International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

Anti-covid repurposed drug Remedesivir: Zhangs catalytic chiral approach

Author Affiliations

  • 1Scrips Pharma, Mallapur, Hyderabad, Telangana-500 076, India

Res.J.chem.sci., Volume 11, Issue (1), Pages 84-86, February,18 (2021)


Herein, author has given glimpses of possible treatment agents for the SARS-COV2 infections and discussed the case study of the synthetic utility of Remedesivir in the present scenario by highlighting Zhangs catalytic asymmetric synthetic approach. It is shown that the chiral bicyclic imidazole catalyst plays vital role for the better stereoselectivity with excellent reactivity via dynamic kinetic asymmetric transformation (DyKAT).


  1. C.D. Savi, D. L Hughes and L. Kvaerno (2020)., Quest for a COVID-19 cure by repurposing small-molecule drugs: Mechanism of action, clinical development, synthesis at scale, and outlook for supply., Org. Proc. Res. Dev. 2020, 24 (6), 940-976.
  2. V. Ravi and B. Haribabu (2020)., Covid-19 in 2020: From despair to hope., Coronaviruses, 1(1), 11-14.
  3. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., and Tan, W. (2020)., A novel coronavirus from patients with pneumonia in China., N. Engl. J .Med., 382(8), 727-733.
  4. a) Jean, S. S., Lee, P. I., and Hsueh, P. R. (2020)., Treatment options for COVID-19: The reality and challenges., J Microbiol Immunol Infect., 53(3), 436-443. b) Gomeni, R., Xu, T., Gao, X., and Bressolle-Gomeni, F. (2020).
  5. Gouglas, D., Thanh, L. T., Henderson, K., Kaloudis, A., Danielsen, T., Hammersland, N. C., Robinson, J. M., Heaton, P. M., and Rottingen, J. A. (2018)., Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study., Lancet Glob Health., 6 (12), e1386-e1396.
  6. Hill, A., Wang, J., Levi, J., Heath, K., and Fortunak, J. (2020)., Minimum costs to manufacture new treatments for COVID-19., J. Virus Erad., 6(2), 61-69.
  7. Vieira, T., Stevens, A., Chtchemelinine, A., Gao, D., Badalov, P., and Huemann, L. (2020)., Development of a large-scale cyanation process using continuous flow chemistry en route to the synthesis of Remdesivir., Org. Process Res. Dev., 24 (10), 2113-2121.
  8. J.A. Al-Tawfiq, A. H. Al-Homoud, Z. A. Memish (2020)., Remdesivir as a possible therapeutic option for the COVID-19., Travel Med Infect Dis.
  9. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., and Xiao, G. (2020)., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro., Cell Res., 30, 269-271.
  10. FDA (2020)., US Food and Drug Administration (FDA), Gilead Sciences, Inc. /download, accessed May 4, 2020.
  11. M. Wang, L. Zhang, X. Huo, Z. Zhang, Q. Yuan, P. Li, J. Chen, Y. Zou, Z. Wu, W. Zhang (2020)., Catalytic asymmetric synthesis of the anti‐COVID‐19 drug Remdesivir., Angew. Chem. Int. Ed., 59 (47), 20814-20819. DOI: 10.1002/anie.202011527
  12. Zhu, R.-Y., Liao, K., Yu, J.-S., and Zhou, J. (2020)., Recent Advances in Catalytic Asymmetric Synthesis of P-Chiral Phosphine Oxides., Acta Chim. Sinica, 78, 193-216.
  13. Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., Neville, S., Carra, E., Lew, W., Ross, B., Wang, Q., Wolfe, L., Jordan, R., Soloveva, V., Knox, J., Perry, J., Perron, M., Stray, K. M., Barauskas, O., Feng, J. Y., Xu, Y., Lee, G., Rheingold, A. L., Ray, A. S., Bannister, R., Strickley, R., Swaminathan, S., Lee, W. A., Bavari, S., Cihlar, T., Lo, M. K., Warren, T. K., and Mackman, R. L. (2017)., Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses., J. Med. Chem., 60(5), 1648-1661.
  14. Warren T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., Larson, N., Strickley, R., Wells, J., Stuthman, K. S., Van Tongeren, S. A., Garza, N. L., Donnelly, G., Shurtleff, A. C., Retterer, C. J., Gharaibeh, D., Zamani, R., Kenny, T., Eaton, B. P., Grimes, E., Welch, L. S., Gomba, L., Wilhelmsen, C. L., Nichols, D. K., Nuss, J. E., Nagle, E. R., Kugelman, J. R., Palacios, G., Doerffler, E., Neville, S., Carra, E., Clarke, M. O., Zhang, L., Lew, W., Ross, B., Wang, Q., Chun, K., Wolfe, L., Babusis, D., Park, Y., Stray, K. M., Trancheva, I., Feng, J. Y., Barauskas, O., Xu, Y., Wong, P., Braun, M. R., Flint, M., McMullan, L. K., Chen, S. S., Fearns, R., Swaminathan, S., Mayers, D. L., Spiropoulou, C. F., Lee, W. A., Nichol, S. T., Cihlar, T., and Bavari, S. (2016)., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys., Nature, 531, 381-385.